216 related articles for article (PubMed ID: 18936896)
1. [Cost-effectiveness evaluation of drugs: multidisciplinary collaboration and transparency are key].
Mueller EA; Kirch W
Med Klin (Munich); 2008 Oct; 103(10):712-6. PubMed ID: 18936896
[TBL] [Abstract][Full Text] [Related]
2. Procedures and methods of benefit assessments for medicines in Germany.
Bekkering GE; Kleijnen J
Eur J Health Econ; 2008 Nov; 9 Suppl 1():5-29. PubMed ID: 18987905
[TBL] [Abstract][Full Text] [Related]
3. [Procedures and methods of benefit assessments for medicines in Germany].
Bekkering GE; Kleijnen J
Dtsch Med Wochenschr; 2008 Dec; 133 Suppl 7():S225-46. PubMed ID: 19034813
[TBL] [Abstract][Full Text] [Related]
4. [Comments by the Working Group for Methods of Economic Evaluation in Health Care (AG MEG) to IQWiG's Draft Guidelines "Methods for Assessment of the Relation of Benefits to Costs in the German Statutory Health Care System"].
Krauth C; John J; Aidelsburger P; Brüggenjürgen B; Hansmeier T; Hessel F; Kohlmann T; Moock J; Rothgang H; Schweikert B; Seitz R; Wasem J;
Gesundheitswesen; 2008 Jun; 70(6):e1-16. PubMed ID: 18661452
[TBL] [Abstract][Full Text] [Related]
5. [Consequences of the German AMNOG for the identification of study objectives to demonstrate clinical efficacy and cost effectiveness of innovative drugs].
Götte D
Dtsch Med Wochenschr; 2012 Feb; 137(6):274-80. PubMed ID: 22270904
[TBL] [Abstract][Full Text] [Related]
6. [GMG proposal for non-prescription medications. Expensive cost savings].
MMW Fortschr Med; 2004 Aug; 146(31-32):48. PubMed ID: 15529713
[No Abstract] [Full Text] [Related]
7. [New institute for additional drug evaluation. Do we really need another barrier?].
Schmidt K
MMW Fortschr Med; 2003 Jul; 145(29-30):55-6. PubMed ID: 12958781
[No Abstract] [Full Text] [Related]
8. From evidence assessments to coverage decisions?: the case example of glinides in Germany.
Kreis J; Busse R
Health Policy; 2012 Jan; 104(1):27-31. PubMed ID: 22136812
[TBL] [Abstract][Full Text] [Related]
9. [Prerequisites in prescribing practice: physician decision processes].
Dierks C
Z Arztl Fortbild Qualitatssich; 1997 Nov; 91(7):620-4. PubMed ID: 9527454
[TBL] [Abstract][Full Text] [Related]
10. [Drug utilization and pharmaceutical cost-containment in germany-perspectives 1 year after enactment of the GMG].
Schlander M
Med Klin (Munich); 2005 Jun; 100(6):314-24. PubMed ID: 15968483
[TBL] [Abstract][Full Text] [Related]
11. [Health insurance discount contracts: problems and risks for the general practitioner in the medical care of patients with chronic illness].
Leutgeb R; Mahler C; Laux G; Weschnetz A; Szecsenyi J
Dtsch Med Wochenschr; 2009 Jan; 134(5):181-6. PubMed ID: 19180404
[TBL] [Abstract][Full Text] [Related]
12. [Physicians and insurance may collaborate on therapy].
MMW Fortschr Med; 2006 Aug; 148(31-32):45. PubMed ID: 16937879
[No Abstract] [Full Text] [Related]
13. [Medication prices in Germany--how are they determined?].
Bruhn C
Dtsch Med Wochenschr; 2010 Oct; 135(39):p34. PubMed ID: 20922657
[No Abstract] [Full Text] [Related]
14. [Legislation by BMGS on evaluation of cost effectiveness].
GFB
Chirurg; 2004 Mar; 75(3):M76. PubMed ID: 15080093
[No Abstract] [Full Text] [Related]
15. Evidence-based benefit assessment of pharmaceuticals as a basis for rational and economical pharmaceutical therapy.
Müller T
Eur J Health Econ; 2008 Nov; 9 Suppl 1():1-3. PubMed ID: 18987904
[No Abstract] [Full Text] [Related]
16. [The costs of new drugs compared to current standard treatment].
Ujeyl M; Schlegel C; Gundert-Remy U
Z Evid Fortbild Qual Gesundhwes; 2013; 107(7):461-7. PubMed ID: 24238023
[TBL] [Abstract][Full Text] [Related]
17. [Scope of the contract for drug therapy. Rebate contracts also for original drugs].
MMW Fortschr Med; 2009 Jul; 151(30-33):80. PubMed ID: 19722473
[No Abstract] [Full Text] [Related]
18. [Pharmacists want to assume penalty].
MMW Fortschr Med; 2006 May; 148(20):55. PubMed ID: 16805194
[No Abstract] [Full Text] [Related]
19. [Limiting prescribing freedom in the hospital].
Jansen C
Z Arztl Fortbild Qualitatssich; 1997 Nov; 91(7):635-7; discussion 638. PubMed ID: 9527459
[TBL] [Abstract][Full Text] [Related]
20. [Evaluating the effectiveness of drugs. "The full potential of a therapy is often only clear after a number of years" (interview by Helmut Laschet)].
Pfundner H
MMW Fortschr Med; 2010 Dec; 152(51-52):10. PubMed ID: 21294362
[No Abstract] [Full Text] [Related]
[Next] [New Search]
